Li-fraumeni syndrome and p53 in 2015: Celebrating their silver anniversary

Clinical and Investigative Medicine

Volumn 39, Issue 1, 2016, Pages E37-E47

  Malkin, David ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; TP53 PROTEIN, HUMAN;

FEMALE; GENETICS; HISTORY; HUMAN; INFANT; LI-FRAUMENI SYNDROME; MALE; MUTATION; PRESCHOOL CHILD;

ANNIVERSARIES AND SPECIAL EVENTS; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; LI-FRAUMENI SYNDROME; MALE; MUTATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84990891386     PISSN: 0147958X     EISSN: 14882353     Source Type: Journal    
DOI: 10.25011/cim.v39i1.26328     Document Type: Article

References (28)

1. Li, FP and Fraumeni, JF 1969. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 71(4):747-752
2. Li, FP et al. 1988. A Cancer Family Syndrome in Twenty-Four Kindreds. Cancer Research 48(18): 5358-62.
3. Birch, JM et al. 1994. Prevalence and Diversity of Constitutional Mutations in the p53 Gene among 21 Li-Fraumeni Families. Cancer Research 54(5): 1298-1304.
4. Eeles, RA et al. 1995. Germline mutations in the TP53 gene. Cancer Surv 25:101-124
5. Chompret, A et al. 2001. Sensitivity and Predictive Value of Criteria for p53 Germline Mutation Screening. J Med Genet 38(1): 43-47.
6. Tinat, J et al. 2009. 2009 Version of the Chompret Criteria for Li Fraumeni Syndrome. J Clin Oncol 27(26): 108-9.
7. Hettmer, S et al. 2014. Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers. Cancer 120(7):1068-75.
8. Rausch, T et al. 2012. Sequencing of the childhood brain tumor medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 148: 59-71.
9. McCuaig, JM et al. 2012. Routine TP53 testing for breast cancer under age 30: ready for prime time? Familial Cancer 11(4):607-13.
10. Lavigueur, A et al. 1989. High incidence of lung, bone and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol Cell Biol 9(9): 3982-91.
11. Malkin, D et al. 1990. Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms. Science 250(4985): 1233-38.
12. http://p53.iarc.fr/
13. Mai, PL et al. 2012. Li-Fraumeni Syndrome: Report of a Clinical Research Workshop and Creation of a Research Consortium. Cancer Genet 205(10): 479-87.
14. Chompret, A et al. 2000. P53 Germline Mutations in Childhood Cancers and Cancer Risk for Carrier Individuals. Brit J Cancer 82(12): 1932-37.
15. Gonzalez, KD et al. 2009. Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline Mutations. 27(8): 1250-6.
16. Wasserman, JD et al. 2015. Prevalence and Functional Consequence of TP53 Mutations in Pediatric Adrenocortical Carcinoma: A Children's Oncology Group Study. J Clin Oncol 33(6):602-9.
17. Bond, G et al. 2004. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591-602.
18. Bougeard, G et al. 2006. Impact of the MDM2 SNP309 and p53 Arg72Pro Polymorphism on Age of Tumour Onset in Li-Fraumeni Syndrome. J Med Genet 43(6): 531-33.
19. Marcel, V et al, 2009. TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis. J Med Gen 46(11): 766-72.
20. Gemignani, F et al. 2004. A TP53 Polymorphism Is Associated with Increased Risk of Colorectal Cancer and with Reduced Levels of TP53 mRNA. Oncogene 23(10): 1954-56.
21. Costa, S et al. 2008. Importance of TP53 Codon 72 and Intron 3 Duplication 16bp Polymorphisms in Prediction of Susceptibility on Breast Cancer. BMC Cancer 8: 32.
22. Hrstka, R, et al. 2009. Intronic Polymorphisms in TP53 Indicate Lymph Node Metastasis in Breast Cancer. Oncology Reports 22(5): 1205-11.
23. Fang, S et al. 2010. Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of TP53 germline mutation carriers. PloS One 5(5):e10813.
24. Id Said B, Malkin D. 2014. A Functional Variant in miR-605 Modifies the Age of Onset in Li-Fraumeni Syndrome. Cancer Genetics 208(1-2): 47-51.
25. Trkova, M et al. 2007. Telomere Length in Peripheral Blood Cells of Germline TP53 Mutation Carriers Is Shorter than that of Normal Individuals of Corresponding Age. Cancer 110(3): 694-702.
26. Tabori, U et al. 2007. Younger Age of Cancer Initiation Is Associated with Shorter Telomere Length in Li-Fraumeni Syndrome. Cancer Res 67(4): 1415-18.
27. Shlien, A et al. 2008. Excessive Genomic DNA Copy Number Variation in the Li-Fraumeni Cancer Predisposition Syndrome. Proc Natl Acad Sciences 105(32): 11264-69.
28. Villani, A et al. 2011. Biochemical and Imaging Surveillance in Germline TP53 Mutation Carriers with Li-Fraumeni Syndrome: A Prospective Observational Study. The Lancet Oncology 12(6): 559-67.